Evira is an innovation part of the Grow Digital Health Midlands 2026 cohort. We spoke to Malin Ramkloo, Head of Clinical Success at Evira. This blog shares insight into their innovation, next steps, their biggest piece of advice innovating in the NHS and their plans for the future.
Tell us about the innovation
Evira is a digital treatment solution for obesity and weight management, designed to provide continuous support between appointments.
Patients use the Evira app together with a connected home scale that does not display the weight numerically. Instead, progress is presented through trend-based graphics, helping patients focus on longer-term development rather than individual measurements. Healthcare professionals can remotely follow progress through a clinical dashboard, communicate with patients and identify when additional support may be needed.
Evira has particular expertise in treating obesity in children and young people, but can also support adult weight-management pathways, including treatment alongside obesity medication. The aim is to complement existing clinical care with structured self-monitoring and more continuous, needs-based follow-up.
What are the plans/next steps for this innovation?
Our main focus now is moving from successful pilots and individual implementations towards more sustainable, long-term adoption across the NHS. This includes building on the experience from the NHS Complications from Excess Weight (CEW) programme and supporting services as they move towards locally commissioned, sustainable arrangements.
We also want to continue strengthening the evidence base. Evira has been used within the national CEW programme, and we look forward to the findings from the NIHR-funded ENHANCE evaluation alongside our growing body of published research and real-world data. Recent peer-reviewed research from Abu Dhabi has also demonstrated comparable outcomes to those observed in Sweden, strengthening the evidence that Evira’s approach can be effective across different cultural contexts and healthcare systems. Several further studies are also ongoing, including research into the combination of digital support and pharmacological treatment, as well as an ongoing multicentre randomised controlled trial across Europe.
At the same time, we are exploring new collaborations across the weight-management pathway. We see particular potential to support patients earlier in the pathway and to provide flexible, longer-term support, rather than limiting support to a fixed short-term programme.
Evira will continue to evolve alongside clinical practice. As treatment pathways evolve, particularly with the increasing use of obesity medication, our aim is to support patients and healthcare teams throughout the treatment journey — supporting self-monitoring, lifestyle change, medication follow-up and ongoing care before, during and after pharmacological treatment.
Ultimately, the aim is for Evira to become a flexible, long-term part of obesity care rather than a time-limited digital intervention. Our ambition is to support patients across different stages of the treatment journey, with the intensity of support adapting as their needs change.
What’s your biggest piece of learning from innovation in the NHS?
One of the biggest learnings is that having a good solution is only one part of successful innovation. How an innovation is implemented matters just as much.
We have seen that different services can use the same technology in very different ways: which patients they offer it to, how it fits into the pathway, who takes responsibility for digital follow-up and how much staff time is allocated to it can all influence implementation.
You also need patience. Information governance, procurement, staffing changes and wider organisational priorities can all affect timelines. Building strong relationships with the people who understand the local pathway is therefore essential.
What are your hopes for the future?
I hope that digital support becomes an integral part of obesity care rather than something that is added only when services have capacity.
Obesity is a long-term condition, but healthcare is still often delivered through relatively infrequent appointments. I would like to see more patients able to access continuous support between those contacts, with treatment intensity adapted according to need.
I also hope we can intervene earlier. If we can support children and families before problems become more severe, while still providing effective long-term support for those requiring specialist or pharmacological treatment, there is an opportunity to improve both patient outcomes and how healthcare resources are used.
What’s the best part of your job?
For me, the best part is still being close to clinical care.
With a background as a dietitian and many years of experience in obesity care, I particularly enjoy speaking with healthcare professionals about the patients they support, the challenges they face, and how Evira can fit into everyday clinical practice. It is especially rewarding when a team tells us that Evira has made their work easier or helped them support a patient in a way they could not before.
I also really value how much I get to learn. My role now involves everything from clinical implementation and research to NHS procurement, commissioning and partnership development — so no two days are quite the same.
How do you feel the Grow programme will support you and your innovation?
The Grow programme is particularly valuable in helping us increase awareness of Evira across the Midlands, where the solution is already being used within several NHS services.
The programme has given us opportunities to take part in regional events, showcase Evira to a wider audience and gain visibility through Grow’s own channels and activities, including the Grow Enabling Fund. It also helps create greater awareness and opens the door to conversations with services that may not otherwise have come across Evira.
The wider support is also very valuable — particularly around understanding how to navigate the NHS, how to position and communicate the innovation, and how to think about pricing, procurement and routes to adoption.
For us, the main value is therefore the combination of regional visibility, practical support and a better understanding of how to build sustainable adoption within the NHS.
Länk: https://evirahealth.co.uk/
https://link.springer.com/article/10.1186/s12887-026-07623-7